Dr Reddy's Laboratories

Nifty50 to hit 29,300 by end-2026? Nomura lists top 20 stock picks

Nomura expects Indian markets to trade in the range of 20-22x one-year forward earnings, assuming risk premia remain low.

Why did Dr Reddy's share rise over 2% in overall subdued market? Details

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Stocks to Watch today, Nov 25: Siemens Energy, Dr Reddy's, Cello, HUDCO

Stocks to Watch Today, November 25, 2025: Dr. Reddy's Labs, Siemens Energy, HUDCO, Sunteck Realty and other stocks will remain in focus; here's why

Canada notice may delay Dr Reddy's semaglutide generic launch

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Q2 results today: Kotak Mahindra, Zen Technologies among 9 firms on Oct 25

Q2FY26 company results: Many firms including 3p Land Holdings, Covance Softsol, Pace Digitek and Samsrita Labs are also to release their July-September quarter earnings reports today

USFDA says 'voluntary action' required at Dr Reddy's Srikakulam unit

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulator for its formulations manufacturing facility at Srikakulam in Andhra Pradesh, classifying the facility as voluntary action indicated. The US Food & Drug Administration (USFDA) had conducted a GMP and a Pre-Approval Inspection (PAI) conducted by at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India, intimated to the exchanges on July 18, 2025, Dr Reddy's Laboratories Ltd said in a regulatory filing. "We wish to inform you that the company has received the Establishment Inspection Report (EIR) on October 20, 2025. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)'," it said, adding the inspection is officially closed. Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or ...

Will this court fight make the world's hottest weight-loss drug cheaper?

Indian pharma takes Novo Nordisk to court over patents that keep Wegovy and Ozempic out of reach - could this slash prices for millions of patients?

Tariff worries, Sun Pharma Q1 miss: Why are pharma stocks falling today?

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.

Dr Reddy Laboratories Q1 profit up 2%, posts best ever quarterly revenue

Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global semaglutide strategy and GLP-1 product pipeline

Dr Reddy's gets 7 USFDA observations after Srikakulam plant inspection

A Form 483 is issued by the US health regulator when inspectors identify conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or relevant guidelines

Dividend stocks: These 4 stocks to go ex-date on July 10; are you eligible?

The ex-dividend date signifies the day from which a stock trades without the entitlement to the declared dividend. Thus, the investors must hold the shares prior to this date to qualify

Dr Reddy's Q4 results preview: Analysts eye 18% jump in PAT; check details

Dr Reddy's Labs Q4 results 2025 date: Dr Reddy's Laboratories is scheduled to announce its fourth quarter (Q4FY25) results on Friday, May 9, 2025

DRL trims workforce costs by 25% amid Revlimid-linked margin strain

There are 21,757 permanent employees on company rolls as on March 31, 2024; cost optimisation to offset margin pressure due to declining Revlimid sales

A year of narrow gains: Just 5 secure keys to trillion-plus vault in FY25

Meanwhile, eight companies dropped off the list: among them were IndusInd Bank, Indian Overseas Bank, Canara Bank, Dr Reddy's Laboratories, Adani Total Gas, and Zydus Lifesciences

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Bio-Thera, Dr. Reddy's partner for biosimilar expansion in Southeast Asia

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases

Bajaj Finance, TaMo, Maruti: Largecap buy, sell stock ideas post Q3 results

Here's a technical outlook on 5 largecap stocks post Q3 results. Charts hint towards a positive bias for Bajaj Finance and Bajaj Auto; whereas a likely fall for Maruti, Tata Motors and Dr. Reddy's.

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets